Aarti Pharmalabs Ltd reports Q2 FY27 consolidated revenue of ₹610.45 crore, up 45.9% YoY, and net profit of ₹71.47 crore.
- Consolidated revenue rose 13.9% QoQ; net profit increased 248.8% YoY but declined 6.1% QoQ. EBITDA margin was approximately 22.2%.
- A ₹2.04 crore stamp-duty provision was booked as an exceptional item; ₹57.46 crore of remaining stamp duty and penalties was disclosed as a contingent liability under court challenge.
- Auditors issued unmodified limited-review conclusions, with emphasis on the stamp-duty case and prior-period restatement for a forward-contract fair-value loss.
- CFO Piyush Lakhani departs October 30; Vibha Thakkar takes over from October 31, 2026.